The measurement of fecal tumor M2-pyruvate kinase (PKM2), overexpressed in tumor cells, has been proposed as a novel tool for detecting colorectal cancer (CRC). However, the sensitivity and specificity of this test varied among studies. The aim of this metaanalysis was to determine the diagnostic accuracy of fecal PKM2 for CRC and to evaluate its utility in the CRC screening. It was compared to guaiac fecal occult blood test (gFOBT) or immunological fecal occult blood test (iFOBT). Through comprehensive literature search, 10 studies met the inclusion criteria and were included. Summary estimates for sensitivity and specificity were calculated by using the bivariate random effect model. The hierarchical summary receiver operating characteristic curve was also undertaken. The overall sensitivity and specificity of fecal PKM2 for detecting CRC were 79% (95% CI 5 75-83%) and 81% (95% CI 5 73-87%), respectively. The summary positive predictive value and negative predictive value were 74% (95% CI 5 56-87%) and 86% (95% CI 5 79-91%), respectively. The pooled diagnostic odds ratio was 16 (95% CI 5 10-26). In head-to-head comparison, the diagnostic odds ratio of PKM2 and gFOBT for CRC were 10.167 (95% CI 5 5.992-17.250) and 6.557 (95% CI 5 3.467-12.403), respectively. The diagnostic odds ratio of PKM2 and iFOBT for CRC were 9.542 (95% CI 5 5.893-15.452) and 67.248 (95% CI 5 16.194-279.26), respectively. The fecal PKM2 test was a diagnostic tool with moderate sensitivity and specificity for detecting CRC. Its diagnostic efficiency was similar to that of gFOBT. Because of its relatively low specificity and positive predict value, fecal PKM2 was not recommended used alone as a screening tool for CRC.Colorectal cancer (CRC) is the third most common cancer in males and second in females. In 2008, over 1.2 million people worldwide were diagnosed with CRC and nearly 608,700 people died from this neoplasm. 1 CRC fulfilled the World Health Organization criteria for mass screening, and early detection of CRC could largely improve the prognosis of diagnosed patients. 2 Colonoscopy is the golden standard for the diagnosis of CRC and its precancerous lesion. However, colonoscopy is expensive and may cause unexpected complications. Moreover, it is uncomfortable and painful for some patients to take colonoscopy examination. Thus, the compliance with colonoscopy for CRC is quite low. 3 Another main type of screening test for CRC is a set of stool-based tests, mainly including guaiac fecal occult blood test (gFOBT) and immunological fecal occult blood test (iFOBT). gFOBT has been demonstrated to reduce the CRC mortality by several large randomized controlled trials. 4,5 However, low sensitivity and high false-positive results of gFOBT may lead to unnecessary invasive tests such as colonoscopy, and the restricted diet and medication limitations may reduce patient compliance. 6 iFOBT test is based on the use of an antibody of human hemoglobin and is not affected by certain foods and drugs, but iFOBT is still not a perfect screening test. I...